Florida biotech billionaire settles SEC stock manipulation case

By Jonathan Stempel

NEW YORK: Florida biotechnology billionaire Phillip Frost has agreed to pay $5.52 million to settle U.S. Securities and Exchange Commission civil charges over his alleged role in “pump-and-dump” schemes that left investors with virtually worthless stock.

The settlement requires Frost, the chairman and chief executive of Miami-based Opko Health Inc, to pay a $5 million fine and about $523,000 representing alleged ill-gotten gains and interest, according to a Thursday filing in Manhattan federal court.

Frost also accepted restrictions on trading penny stocks. Opko agreed to pay a $100,000 fine in a related settlement.

Neither defendant admitted or denied wrongdoing in agreeing to the settlements, which will end “potentially expensive, contentious and time-consuming litigation,” Frost said in a statement provided by Opko. Court approval is required.

A lawyer for Frost had no immediate additional comment.

Frost was among 10 people and 10 associated entities charged by the SEC on Sept. 7 with involvement from 2013 to 2018 in the manipulation of three companies’ share prices.

The SEC accused various defendants of buying large blocks of penny stocks at steep discounts, promoting the shares, and then quietly selling their stock at inflated prices, generating more than $27 million of improper gains.

Frost was allegedly involved in two of the schemes, the SEC said.

Now 82, Frost is worth $1.9 billion, Forbes magazine said on Thursday.

He had been chairman and chief executive of Ivax Corp before selling that drugmaker for $7.4 billion in 2006 to Israel-based Teva Pharmaceutical Industries Ltd, where he later served as chairman.

  • Related Posts

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Eli Lilly working on single-dose drug to be administered via IV for long-term gain Mumbai: For millions of heart patients struggling with elevated levels of cholesterol, there is a ray…

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Regeneron Pharmaceuticals, Inc. has announced plans to establish the Regeneron Global Capability Centre (GCC) in Hyderabad, a strategic investment that deepens its global operations and scales business functions to advance…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    Gene Therapy for Cholesterol: Initial Test Results Cheer

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    US Biotech Regeneron to launch Global Capability Centre in Hyderabad

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Popped the Pill, Paid the Price to Potentially Fatal Skin Syndrome

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Former Advisor to India’s Union Health Ministry gets Quite a Feather in his Cap

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    Alembic Pharma Secures USFDA Approval for Generic Synthroid Tablets

    STF busts fake meds racket spread across 6 states

    STF busts fake meds racket spread across 6 states